JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

Home・Akciju saraksts・Cogent Biosciences Inc

Cogent Biosciences Inc

Slēgts

36.1 -0.17

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

35.36

Max

36.45

Galvenie mērījumi
By Trading Economics
Ienākumi	-22M -102M
Darbinieki	258
EBITDA	-30M -109M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+44.41% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	398M 6B
Iepriekšējā atvēršanas cena	36.27
Iepriekšējā slēgšanas cena	36.1

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

4.88 / 5.87 Atbalsts un pretestība

Cogent Biosciences Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 24. apr. 00:00 UTC

Peļņas

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

2026. g. 24. apr. 00:00 UTC

Peļņas

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

2026. g. 23. apr. 23:47 UTC

Tirgus saruna

Gold Edges Lower Amid Ongoing Concerns Over Higher Inflation -- Market Talk

2026. g. 23. apr. 23:43 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 23. apr. 23:43 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 23. apr. 23:43 UTC

Tirgus saruna

Nikkei May Decline Amid Uncertainty Over U.S.-Iran Conflict -- Market Talk

2026. g. 23. apr. 23:13 UTC

Iegādes, apvienošanās, pārņemšana

Trump on Spirit Airlines: 'I Think We'd Just Buy It' -- Update

2026. g. 23. apr. 22:33 UTC

Peļņas

Intel Shares Jump 20% as AI Agents Drive Big Growth -- WSJ

2026. g. 23. apr. 22:17 UTC

Peļņas

PLS Executed Offtake Agreement With Ronbay

2026. g. 23. apr. 22:17 UTC

Peļņas

PLS Secured Up to A$38.1M in Australia Government ARENA Grant Funding

2026. g. 23. apr. 22:16 UTC

Peļņas

PLS Commences Commissioning of Midstream Demonstration Plant

2026. g. 23. apr. 22:15 UTC

Peļņas

PLS Group Reaffirms FY26 Guidance for All Metrics

2026. g. 23. apr. 22:14 UTC

Peļņas

PLS Group 3Q Cash Margin From Operations A$461M at March 31

2026. g. 23. apr. 22:14 UTC

Peļņas

PLS Group 3Q Cash Balance A$1.455 Billion at March 31

2026. g. 23. apr. 22:13 UTC

Peļņas

PLS Group 3Q Unit Operating Cost A$733/Ton CIF, Up 2% on 2Q

2026. g. 23. apr. 22:12 UTC

Peļņas

Correct: PLS Group 3Q Unit Operating Cost A$520/Ton FOB, Down 11% on 2Q

2026. g. 23. apr. 22:12 UTC

Peļņas

PLS Group 3Q Unit Operating Cost US$520/Ton FOB, Down 11% on 2Q

2026. g. 23. apr. 22:11 UTC

Peļņas

PLS Group 3Q Realized Price US$1,867/Ton, Up 61% on 2Q

2026. g. 23. apr. 22:10 UTC

Peļņas

PLS Group 3Q Revenue A$567,000, Up 52% on 2Q

2026. g. 23. apr. 22:09 UTC

Peļņas

PLS Group 3Q Sales 195,700 Tons, Down 16% on 2Q

2026. g. 23. apr. 22:08 UTC

Peļņas

PLS Group 3Q Production 232,400 Tons, Up 12% on 2Q

2026. g. 23. apr. 22:04 UTC

Peļņas

Intel Sales Rise 7% as AI Agents Drive Growth -- WSJ

2026. g. 23. apr. 21:56 UTC

Tirgus saruna

Peļņas

Intel Points to Growing Role of CPUs Amid AI Shifts -- Market Talk

2026. g. 23. apr. 21:48 UTC

Iegādes, apvienošanās, pārņemšana

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

2026. g. 23. apr. 21:27 UTC

Peļņas

Intel CFO: All Demand Signals Point to Growing Role of CPUs in AI Era

2026. g. 23. apr. 21:25 UTC

Peļņas

Intel CFO Expects Factories to Continue Increasing Supply in 3Q, 4Q, but at More Measured Pace Than Previously Expected

2026. g. 23. apr. 21:24 UTC

Peļņas

SAP Stock Rebounds From Software Slaughter. The Cloud Boosted Europe's Tech Titan. -- Barrons.com

2026. g. 23. apr. 21:24 UTC

Peļņas

Blackstone Stock Falls After Earnings. Private Credit Remains in Focus. -- Barrons.com

2026. g. 23. apr. 21:21 UTC

Peļņas

Intel to Look for Unconventional Way to Boost Manufacturing Capacity Through Musk's Terafab Project, CEO Says

2026. g. 23. apr. 21:21 UTC

Peļņas

Intel CEO: He, Elon Musk Believe Global Semiconductor Supply Isn't Keeping Up With Accelerating Demand

Salīdzinājums

Cenas izmaiņa

Cogent Biosciences Inc Prognoze

Cenas mērķis

By TipRanks

44.41% augšup

Prognoze 12 mēnešiem

Vidējais 52.55 USD 44.41%

Augstākais 64 USD

Zemākais 35 USD

Pamatojoties uz 12 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Cogent Biosciences Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

12 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 12 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Cogent Biosciences Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

4.88 / 5.87Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.